bb Lapatinib + Capecitabine | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic | Brain metastasis (n = 58) | No Brain metastasis (n = 128) | Pvaluea | No Prior capecitabine (n = 95) | Prior capecitabine (n = 91) | Pvaluea | Total (n = 186†) | |||||
No. | % | No. | % | No. | % | No. | % | No. | % | |||
Median age, yrs (range) | 46.5 | (27-70) | 49 | (27-71) | 0.170 | 48 | (27-71) | 47 | (29-70) | 0.960 | 48 | (27-71) |
<50 | 38 | (65.5) | 67 | (52.3) | 0.1111 | 53 | (55.8) | 52 | (57.1) | 0.8832 | 105 | (56.2) |
≥50 | 20 | (34.5) | 61 | (47.7) | 42 | (44.2) | 39 | (42.9) | 82 | (43.9) | ||
Hormone receptor | ||||||||||||
ER + and/or PR+ | 28 | (49.1) | 45 | (35.4) | 0.103 | 36 | (38.3) | 37 | (41.1) | 0.764 | 73 | (39.7) |
ER- and PR- | 29 | (50.9) | 82 | (64.6) | 58 | (61.7) | 53 | (58.9) | 111 | (60.3) | ||
Unknown | 1 | (1.7) | 1 | (0.8) | 1 | (1.0) | 1 | (1.1) | 2 | (1.1) | ||
No. metastatic sites | ||||||||||||
1 | 5 | (8.9) | 17 | (13.6) | 0.174 | 14 | (15.2) | 8 | (9.0) | 0.042 | 22 | (12.2) |
2 | 15 | (26.8) | 47 | (37.6) | 37 | (40.2) | 25 | (28.1) | 62 | (34.3) | ||
≥ 3 | 36 | (64.3) | 61 | (48.8) | 41 | (44.6) | 56 | (62.9) | 97 | (53.6) | ||
Unknown | 2 | (3.4) | 3 | (2.3) | 3 | (3.2) | 2 | (2.2) | 5 | (2.7) | ||
Pattern of metastasis | ||||||||||||
Visceral only | 18 | (31.6) | 56 | (45.5) | 0.161 | 34 | (37.8) | 40 | (44.4) | 0.617 | 74 | (41.1) |
Non-visceral only | 8 | (14.0) | 11 | (8.9) | 11 | (12.2) | 8 | (8.9) | 19 | (10.6) | ||
Both | 31 | (54.4) | 56 | (45.5) | 45 | (50.0) | 42 | (46.7) | 87 | (48.3) | ||
Unknown | 1 | (1.7) | 5 | (3.9) | 5 | (5.3) | 1 | (1.1) | 6 | (3.2) | ||
Prior capecitabine b | 30 | (51.7) | 61 | (47.7) | 0 | (0.0) | 91 | (48.9) | 91 | (48.9) | ||
> 3 Prior chemotherapy regimens | 22 | (37.9) | 45 | (35.2) | 10 | (10.5) | 57 | (62.6) | 67 | (36.0) | ||
Median duration of trastuzumab, wks (range) | 35.4 | (4.0-113.6) | 20.6 | (0.1-105.0) | 0.016 | 27.3 | (0.1-104.4) | 21.6 | (3.0-113.6) | 0.252 | 24.1 | (0.1-113.6) |
Interval from last dose of trastuzumab prior to study entry, wks | ||||||||||||
Median (range) | 11.6 | (2.7-146.6) | 20.9 | (0.1-172.3) | 0.365 | 7.7 | (0.1-172.3) | 24.9 | (1.4-160.9) | 0.001 | 14.6 | (0.1-172.3) |
< 4 | 3 | (5.2) | 16 | (12.6) | 0.341 | 14 | (14.7) | 5 | (5.6) | <0.001 | 19 | (10.3) |
4 - 8 | 17 | (29.3) | 33 | (26.0) | 37 | (39.0) | 13 | (14.4) | 50 | (27.0) | ||
>8 | 38 | (65.5) | 78 | (61.4) | 44 | (46.3) | 72 | (80.0) | 116 | (62.7) | ||
Unknown | 0 | (0.0) | 1 | (0.8) | 0 | (0.0) | 1 | (1.1) | 1 | (0.5) |